Shares of Medpace Hldgs (NASDAQ:MEDP) were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 65.62% year over year to $1.06, which beat the estimate of $0.99.
Revenue of $278,293,000 up by 35.76% year over year, which beat the estimate of $272,100,000.
Guidance
Earnings guidance hasn’t been issued by the company for now.
Medpace Hldgs hasn’t issued any revenue guidance for the time being.
Price Action
Company’s 52-week high was at $196.12
52-week low: $105.36
Price action over last quarter: Up 8.82%
Company Overview
Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.
